Slide 1: Making life easier
Conference call presentation Q1 2023/24 Making life easier Strive25: Sustainable Growth Leadership Ostomy Care | Continence Care | Advanced Wound Care | Interventional Urology | Voice and Respiratory Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Q1 2023/24 financial result in line with guidance
NEW IMAGE Q1 2023/24 financial result in line with guidance Otto: add picture with Peristeen Light Update picture Organic Reported ROIC growth EBIT margin 8% 28% * * 15% ** *before special items **after tax and before special items 3 Peristeen® Light
Slide 4: Solid start to the year with 8% organic growth in Q1, driven by Chronic Care
Solid start to the year with 8% organic growth in Q1, driven by Chronic Care Q1 2023/24 revenue by business area Q1 2023/24 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm growth Ost
Slide 5: Q1 reported revenue grew 8% with ~4%-points from the Kerecis acquisition
Q1 reported revenue grew 8% with ~4%-points from the Kerecis acquisition and significant negative impact from currencies Q1 2023/24 Revenue development (mDKK) Q1 2023/24 highlights • Reported revenue increased by DKK 501 million or 8% vs. last year • Organic growth was 8% or DKK 459 million, driven
Slide 6: Reported EBIT margin of 28% in Q1, with significant currency headwind
Reported EBIT margin of 28%1 in Q1, with significant currency headwind and ~100 basis points negative impact from Kerecis Q1 2023/24 EBIT margin development before special items (%) Q1 2023/24 highlights • Gross margin was 68%, on par with last year • Positive impact from: decrease in freight rates,
Slide 7: Q1 FCF of DKK 1,521 million and FCF-to-sales ratio of 23%
Q1 FCF of DKK 1,521 million and FCF-to-sales ratio of 23%, reflecting improved operating cash flow, driven by lower income tax paid FCF development1 Q1 2023/24 highlights • Free cash flow for Q1 2023/24 was an inflow of DKK 1,521 million compared to an inflow of DKK 212 million last year 98 • Operat
Slide 8: FY 2023/24: Unchanged organic growth guidance of around 8% and EBIT margin guidance of 27-28%
FY 2023/24: Unchanged organic growth guidance of around 8% and EBIT margin* guidance of 27-28% Organic revenue growth Around 8% Reported revenue growth in DKK Around 11% Reported EBIT margin* 27-28% Effective tax rate Around 22% Capital expenditures Around 1.4 bn DKK *before special items 8
Slide 9: Our Strive25 strategy supports continued long-term value creation
Our Strive25 strategy supports continued long- term value creation through revenue and earnings growth Long-term financial guidance 8-10% more than 30% organic growth EBIT margin p.a.1 beyond 2024/252 1 Raised to 8-10%, from previously 7-9%, on July 7 as a result of the acquisition of Kerecis, expec
Slide 10: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding